Tim-3 Expression in Cervical Cancer Promotes Tumor Metastasis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Jan 22

PMID 23335978

Citations 81

Authors

Yang Cao

Xiaoxi Zhou

Xiaoyuan Huang

Qinlu Li

Lili Gao

Lijun Jiang

Mei Huang

Jianfeng Zhou

Affiliations

Soon will be listed here.

Abstract

Background: T cell immunoglobulin mucin-3 (Tim-3) has been identified as a negative regulator of anti-tumor immunity. Recent studies highlight the important role of Tim-3 in the CD8(+) T cell exhaustion that takes place in both human and animal cancer models. However, the nature of Tim-3 expression in the tumor cell and the mechanism by which it inhibits anti-tumor immunity are unclear. This present study aims to determine Tim-3 is expressed in cervical cancer cells and to evaluate the role of Tim-3 in cervical cancer progression.

Methodology: A total of 85 cervical tissue specimens including 43 human cervical cancer, 22 cervical intraepithelial neoplasia (CIN) and 20 chronic cervicitis were involved. Tim-3 expression in tumor cells was detected and was found to correlate with clinicopathological parameters. Meanwhile, expression of Tim-3 was assessed by RT-PCR, Western Blot and confocal microscopy in cervical cancer cell lines, HeLa and SiHa. The migration and invasion potential of Hela cells was evaluated after inhibiting Tim-3 expression by ADV-antisense Tim-3.

Conclusions: We found that Tim-3 was expressed at a higher level in the clinical cervical cancer cells compared to the CIN and chronic cervicitis controls. We supported this finding by confirming the presence of Tim-3 mRNA and protein in the cervical cell lines. Tim-3 expression in tumor cells correlated with clinicopathological parameters. Patients with high expression of Tim-3 had a significant metastatic potential, advanced cancer grades and shorter overall survival than those with lower expression. Multivariate analysis showed that Tim-3 expression was an independent factor for predicting the prognosis of cervical cancer. Significantly, down-regulating the expression of Tim-3 protein inhibited migration and invasion of Hela cells. Our study suggests that the expression of Tim-3 in tumor cells may be an independent prognostic factor for patients with cervical cancer. Moreover, Tim-3 expression may promote metastatic potential in cervical cancers.

Citing Articles

Retraction: Tim-3 Expression in Cervical Cancer Promotes Tumor Metastasis.

PLoS One. 2024; 19(7):e0308113.

PMID: 39052637 PMC: 11271886. DOI: 10.1371/journal.pone.0308113.

The effects of HIV and oncogenic human papillomavirus on the tumor immune microenvironment of penile squamous cell carcinoma.

Mumba C, Muhimbe Z, Mapulanga V, Kawimbe M, Mutale K, Hamasuku A PLoS One. 2024; 19(5):e0300729.

PMID: 38691575 PMC: 11062539. DOI: 10.1371/journal.pone.0300729.

Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party.

Lu C, Tan Y Mol Ther Oncol. 2024; 32(1):200773.

PMID: 38596295 PMC: 10905042. DOI: 10.1016/j.omton.2024.200773.

CircPVT1 promotes migration and invasion by regulating miR-490-5p/HAVCR2 axis in osteosarcoma cells.

Zhou C, Balmer L, Song M, Wu K, Wang W, Wang H J Cell Mol Med. 2024; 28(8):e18269.

PMID: 38568056 PMC: 10989635. DOI: 10.1111/jcmm.18269.

Pan-cancer analysis of TIM-3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity.

Lim J, Kurzrock R, Nishizaki D, Miyashita H, Adashek J, Lee S Cancer Med. 2023; 13(1):e6844.

PMID: 38132831 PMC: 10807558. DOI: 10.1002/cam4.6844.

References

Sakuishi K, Jayaraman P, Behar S, Anderson A, Kuchroo V . Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol. 2011; 32(8):345-9. PMC: 3164311. DOI: 10.1016/j.it.2011.05.003. View

Zhou Q, Munger M, Veenstra R, Weigel B, Hirashima M, Munn D . Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011; 117(17):4501-10. PMC: 3099570. DOI: 10.1182/blood-2010-10-310425. View

Kloth J, Gorter A, Fleuren G, Oosting J, Uljee S, Ter Haar N . Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma. J Pathol. 2008; 215(3):222-30. DOI: 10.1002/path.2347. View

Huang X, Bai X, Cao Y, Wu J, Huang M, Tang D . Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. J Exp Med. 2010; 207(3):505-20. PMC: 2839144. DOI: 10.1084/jem.20090397. View

Alderton G . Metastasis. Exosomes drive premetastatic niche formation. Nat Rev Cancer. 2012; 12(7):447. DOI: 10.1038/nrc3304. View

Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher I, Sander C . Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010; 207(10):2175-86. PMC: 2947081. DOI: 10.1084/jem.20100637. View

Li S, Wang N, Brodt P . Metastatic cells can escape the proapoptotic effects of TNF-α through increased autocrine IL-6/STAT3 signaling. Cancer Res. 2011; 72(4):865-75. DOI: 10.1158/0008-5472.CAN-11-1357. View

Zhou J, Gao Q, Chen G, Huang X, Lu Y, Li K . Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability. Clin Cancer Res. 2005; 11(23):8431-40. DOI: 10.1158/1078-0432.CCR-05-1085. View

Sakuishi K, Apetoh L, Sullivan J, Blazar B, Kuchroo V, Anderson A . Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010; 207(10):2187-94. PMC: 2947065. DOI: 10.1084/jem.20100643. View

10.

Kikushige Y, Shima T, Takayanagi S, Urata S, Miyamoto T, Iwasaki H . TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 2010; 7(6):708-17. DOI: 10.1016/j.stem.2010.11.014. View

11.

No J, Kim M, Jeon Y, Kim Y, Song Y . Human papillomavirus vaccine: widening the scope for cancer prevention. Mol Carcinog. 2011; 50(4):244-53. DOI: 10.1002/mc.20657. View

12.

Norde W, Hobo W, van der Voort R, Dolstra H . Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. Blood. 2012; 120(4):728-36. DOI: 10.1182/blood-2012-02-412510. View

13.

Tu B, Du L, Fan Q, Tang Z, Tang T . STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma. Cancer Lett. 2012; 325(1):80-8. DOI: 10.1016/j.canlet.2012.06.006. View

14.

Kong L, Gelbard A, Wei J, Reina-Ortiz C, Wang Y, Yang E . Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin Cancer Res. 2010; 16(9):2550-61. PMC: 2936966. DOI: 10.1158/1078-0432.CCR-10-0279. View

15.

Wiener Z, Kohalmi B, Pocza P, Jeager J, Tolgyesi G, Toth S . TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells. J Invest Dermatol. 2006; 127(4):906-14. DOI: 10.1038/sj.jid.5700616. View

16.

Jan M, Chao M, Cha A, Alizadeh A, Gentles A, Weissman I . Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci U S A. 2011; 108(12):5009-14. PMC: 3064328. DOI: 10.1073/pnas.1100551108. View

17.

Anderson A . Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol. 2012; 24(2):213-6. DOI: 10.1016/j.coi.2011.12.005. View

18.

Ibrahim R, Frederickson H, Parr A, Ward Y, Moncur J, Khleif S . Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism. Cancer. 2006; 106(5):1065-77. DOI: 10.1002/cncr.21697. View

19.

Geng H, Zhang G, Li D, Zhang H, Yuan Y, Zhu H . Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell-mediated immune response. J Immunol. 2006; 176(3):1411-20. DOI: 10.4049/jimmunol.176.3.1411. View